Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
|Articles|October 22, 2021
Spectrum Chemical Names Top 10 Chemicals Impacting Quality of Life
Author(s)BioPharm International Editors
Spectrum Chemical scientists give a shout-out to 10 chemicals impacting quality of life in conjunction with National Chemistry Week.
Advertisement
In conjunction with National Chemistry Week (Oct. 17- 23, 2021), Spectrum Chemical Mfg. Corp scientists compiled a list of their top 10 chemicals impacting quality of life, according to the company’s Oct. 2021 press release. This list is based on multiple factors, including contributions to saving lives, ending suffering, and enabling technological advancements that have provided more communication channels, improved access to information, and modernized the healthcare industry.
The “Top 10 Chemicals that Have Impacted Quality of Life”, as selected by Spectrum Chemical Mfg. Corp scientists, are as follows:
- Penicillin
- Insulin
- Progesterone
- Propylene
- Sulfuric Acid
- Methane
- Adenosine Triphosphate
- Various Lithium Oxides
- Silicon
- Ether
“Chemistry plays an essential role in improving the quality of life, as highlighted by the many chemists, scientists, and medical professionals playing a key role in the battle against COVID-19 and other diseases,” said Russell Kneipp, COO, Spectrum Chemical, in the press release.
National Chemistry Week is an annual event to build public awareness of the importance of chemistry to quality of life.
Source:
Advertisement
Related to this article
FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
Inebilizumab (Uplizna) cut MG-ADL scores by 1.9 points versus placebo, supporting its approval in Japan for myasthenia gravis.
Regulatory approvals, trial data, and major licensing deals in 2026 are accelerating subcutaneous biologics, cutting patient burden and reshaping biopharma strategy.
Insilico's Longevity Vaccines use circular mRNA to arm T cells against aging's earliest culprit cells, starting with immune rejuvenation.
GSK's new trispecific TCE targets 2 tumor antigens plus T cells, aiming to improve on the tolerability of current myeloma therapies.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Phio's PH-762 posted a 70% response rate in skin cancer, supporting its FDA briefing package for a planned phase 2b trial.
Advertisement
Advertisement